Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Ola Electric shares hit 5% upper circuit on foray into energy storage biz with Ola Shakti
16/10/2025
Nestle India shares jump 5% despite Q2 profit tumbling 24% YoY ; here’s why
16/10/2025
Cian Agro shares hit 5% lower circuit after 16-day upper circuit run. Stock still up over 8,400% in 2 years
16/10/2025
Nestle to axe 16,000 jobs as new CEO targets sales growth
16/10/2025
US agency blames faulty engineering for Titan submersible disaster
16/10/2025
Staying calm amid market noise : Rajeev Thakkar’s perspective on investing in transitioning sectors
16/10/2025
